This finding underscores that PBC may occur as a clinical phenotype of IRF2BP2 deficiency even in the absence of serological markers, underlining the significance of considering biopsy-proven PBC in patients with immunodeficiency exhibiting hepatobiliary abnormalities. This evidence concerns the gene IRF2BP2 and immune system disorder.